The companies have to submit these details by March 3.

India’s drug pricing regulator has sought details of the price movement and inventory of 58 key ingredients that go into the making of finished drug dosages, seeking to ensure that the Cvoid-19 outbreak doesn’t cause the Chinese-dependent supply chain to snap and result in an undue rise in retail prices of medicines locally.

The regulator has told drug companies and industry groupings to submit the price movement, production details and inventory of active pharmaceutical ingredients (APIs) and key starting material (KSM) of 58 crucial APIs that are imported from China.

The APIs are used in antibiotics, vitamins and other essential medicines, and are heavily sourced from China.

These APIs are paracetamol, aspirin, azithromycin, amoxicillin, ofloxacin, metronidazole; vitamins such as B12, B1, B6, and E; female hormone progesterone; HIV drugs lopinavir and ritonavir; and blood pressure-controlling drug valsartan.

The companies have to submit these details by March 3.

The government has been examining the impact of the shutdown in China on the pharmaceutical sector in India.